Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.

ABSTRACT:

Background

A 31-gene expression profile (GEP) test that provides risk classification of cutaneous melanoma (CM) patients has been validated in several retrospective studies. The objective of the reported study was a prospective evaluation of the GEP performance in patients enrolled in two clinical registries.

Methods

Three-hundred twenty two CM patients enrolled in the EXPAND (NCT02355587) and INTEGRATE (NCT02355574) registries met the criteria of age ≥ 16 years, successful GEP result and ≥1 follow-up visit for inclusion in this interim analysis. Primary endpoints were recurrence-free (RFS), distant metastasis-free (DMFS), and overall survival (OS).

Results

Median follow-up was 1.5 years for event-free patients. Median age for subjects was 58 years (range 18-87) and m

SUBMITTER: Hsueh EC 

PROVIDER: S-EPMC5576286 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature